-
Humana Analysts More Bullish After Health Insurance Fee Repeal
Friday, January 3, 2020 - 2:34pm | 478Read More...Humana Inc (NYSE: HUM) is likely to benefit from the permanent repeal of the health insurance fee, or HIF, beginning Jan. 1, 2021, rendering the stock more attractive, according to sell-side analysts. The Analysts JPMorgan analyst Gary Taylor reiterated an Overweight rating on Humana and...
-
Molina Wins New Bulls On Cost Saving, Margin Opportunities
Tuesday, January 8, 2019 - 1:57pm | 532Read More...A bullish presentation by Molina Healthcare, Inc. (NYSE: MOH) bolstered the confidence of Street analysts Tuesday. The Analysts JPMorgan analyst Gary Taylor upgraded Molina from Neutral to Overweight and raised the price target from $127 to $150. MUFG analyst Jason Twizell upgraded...
-
Insurance Adjustment: Molina Healthcare Downgraded By JPMorgan On Valuation
Wednesday, June 27, 2018 - 11:54am | 318Read More...Shares of Molina Healthcare, Inc. (NYSE: MOH) are now fairly valued after eclipsing the $90 level, according to JPMorgan. The Analyst JPMorgan's Gary Taylor downgraded Molina from Overweight to Neutral with a price target lifted from $91 to $106. The Thesis Molina is a "pure play...
-
Molina Healthcare's Issues Aren't Permanent, JPMorgan Says Amid Upgrade
Tuesday, January 16, 2018 - 11:54am | 351Read More...Molina Healthcare, Inc. (NYSE: MOH) and CEO Joe Zubretsky made quite an impression at the recent JPMorgan Healthcare conference, and Wall Street took notice. The Analyst JPMorgan analyst Gary Taylor upgraded Molina stock from Neutral to Overweight and raised his price target from $65 to $103....
-
American Kidney Fund Legal Issues A Major Overhang For DaVita Shares
Monday, October 9, 2017 - 12:00pm | 363Read More...JPMorgan said in a note it views the ongoing legal battle between payors, dialysis providers and the American Kidney Fund as a major overhang for Davita Inc (NYSE: DVA) shares. As such, the firm downgraded shares of DaVita from Neutral to Underweight and lowered its price target from $66 to $51....
-
Medicare Advantage Could Boost WellCare Investors, Says JPMorgan
Monday, February 22, 2016 - 4:11pm | 206Read More...Shares of WellCare Health Plans, Inc. (NYSE: WCG) surged as much as 12 percent Monday after JPMorgan upgraded the stock to Overweight from Neutral"on the back of recent proposal by CMS to hike Medicare Advantage rates. The Centers for Medicare and Medicaid Services on Friday announced a...
-
UPDATE: Citigroup Lowers PT on Quest Diagnostics, Two Shots are Enough
Wednesday, December 11, 2013 - 2:54pm | 166Read More...In a report published Wednesday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Quest Diagnostics (NYSE: DGX), but lowered the price target from $59.00 to $58.00. In the report, Citigroup noted, “Both LH and BRLI have recently cited material reimbursement and industry pressures; we...
-
UPDATE: Citigroup Lowers PT on Laboratory Corp. of America Holdings on Surprisingly Weak 2014 Guidance
Wednesday, December 11, 2013 - 2:53pm | 121Read More...In a report published Wednesday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Laboratory Corp. of America Holdings (NYSE: LH), but lowered the price target from $101.00 to $93.00. In the report, Citigroup noted, “On Tuesday night LH released surprisingly weak initial 2014 ‘cash'...
-
UPDATE: Citigroup Reiterates on Universal Health Services on Good Market Position
Thursday, November 21, 2013 - 11:40am | 115Read More...In a report published Thursday, Citigroup analyst Gary Taylor reiterated a Buy rating on Universal Health Services (NYSE: UHS), and raised the price target from $84.00 to $92.00. In the report, Citigroup noted, “We are raising our 12-month price target on shares of UHS from $84 to $92. We...
-
UPDATE: Citigroup Lowers PT on Quest Diagnostics Following Disappointing 3Q13 Results
Friday, October 11, 2013 - 11:34am | 118Read More...In a report published Friday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Quest Diagnostics (NYSE: DGX), but lowered the price target from $64.00 to $60.00. In the report, Citigroup noted, “DGX previewed disappointing 3Q13 results this morning after mounting a spirited defense of...
-
UPDATE: Citigroup Downgrades Community Health Systems on Lowered Forward Estimates
Monday, September 9, 2013 - 10:59am | 151Read More...In a report published Monday, Citigroup analyst Gary Taylor downgraded the rating on Community Health Systems (NYSE: CYH) from Buy to Neutral, and lowered the price target from $60.00 to $42.00. In the report, Citigroup noted, “We are downgrading our rating on CYH from Buy to Neutral and lowering...
-
UPDATE: Citigroup Raises PT on Community Health Systems Following HMA Acquisition Agreement
Wednesday, July 31, 2013 - 11:02am | 143Read More...In a report published Wednesday, Citigroup analyst Gary Taylor reiterated a Buy rating on Community Health Systems (NYSE: CYH), and raised the price target from $50.00 to $60.00. In the report, Citigroup noted, “CYH agreed to acquire HMA for $13.78/share + another possible $1/share via a...
-
Psychiatric Solutions (PSYS) Downgraded After Deal Announced
Tuesday, May 18, 2010 - 2:45pm | 219Read More...Citi Investment Research & Analysis analyst Gary Taylor downgraded his rating for shares of Psychiatric Solutions, Inc. (Nasdaq: PSYS) to Hold, while raising his price target to $33.75 per share, from the previous price target of $25. Taylor raised his price target to the announced price that...
-
Citi Rates Universal Health Services (UHS) A Buy
Tuesday, May 18, 2010 - 2:32pm | 154Read More...Citi Investment Research & Analysis analyst Gary Taylor reiterated his Buy rating for shares of Universal Health Services, Inc (NYSE: UHS), with a price target of $47 per share. Taylor said that his newco model for Universal Health Services, Inc / Psychiatric Solutions, Inc. (Nasdaq: PSYS)...
